Renoprotective role of ACE inhibitors in diabetic nephropathy.
作者信息
Mogensen C E
机构信息
Medical Department M, Endocrinology and Diabetes, Aarhus Kommunehospital, University Hospital of Aarhus, Denmark.
出版信息
Br Heart J. 1994 Sep;72(3 Suppl):S38-45. doi: 10.1136/hrt.72.3_suppl.s38.
Abstract
摘要
相似文献
1
Renoprotective role of ACE inhibitors in diabetic nephropathy.
Br Heart J. 1994 Sep;72(3 Suppl):S38-45. doi: 10.1136/hrt.72.3_suppl.s38.
2
[Renal histopathology of diabetic nephropathy].
Nihon Rinsho. 2005 Jun;63 Suppl 6:314-9.
3
Should all diabetic patients take ACE inhibitors, even those without proteinuria?
Cleve Clin J Med. 1999 Apr;66(4):208-9. doi: 10.3949/ccjm.66.4.208.
4
[Renoprotective effects of ACE inhibitors and AT1 antagonists on diabetic nephropathy beyond blood pressure control].
Nihon Rinsho. 2005 Jun;63 Suppl 6:394-9.
5
Diabetes and ACE inhibitors.
J Hum Hypertens. 1990 Oct;4 Suppl 4:63-6; discussion 66-7.
6
Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
J Hypertens Suppl. 1996 Dec;14(6):S11-4.
7
[Should normotensive diabetic patients with microalbuminuria be treated with angiotensin converting enzyme inhibitors?].
Ugeskr Laeger. 2002 Apr 1;164(14):1907-9.
8
ACE inhibition in diabetic nephropathy.
J Diabet Complications. 1990 Apr-Jun;4(2):86-7. doi: 10.1016/0891-6632(90)90043-5.
9
Controversies on the prevention of diabetic nephropathy.
J Pediatr Endocrinol Metab. 1998 Apr;11 Suppl 2:365-9.
10
Diabetic nephropathy: are we making progress in delaying renal failure?
Clin Biochem. 1993 Aug;26(4):318-9. doi: 10.1016/0009-9120(93)90136-t.
引用本文的文献
1
An encounter with enalapril-induced resistant, life-threatening angioedema at rural health center in Botswana.
Indian J Crit Care Med. 2016 Oct;20(10):613-616. doi: 10.4103/0972-5229.192060.
2
What are the most effective interventions in preventing diabetic foot ulcers?
Int Wound J. 2008 Jun;5(3):425-33. doi: 10.1111/j.1742-481X.2007.00378.x.
3
Lisinopril. A review of its pharmacology and use in the management of the complications of diabetes mellitus.
Drugs. 1997 Jun;53(6):1081-105. doi: 10.2165/00003495-199753060-00010.
本文引用的文献
1
Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis.
Hypertension. 1993 Jun;21(6 Pt 1):786-94. doi: 10.1161/01.hyp.21.6.786.
2
Diabetic microalbuminuria and cilazapril.
Am J Med. 1993 Apr 23;94(4A):58S-60S.
3
Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients.
Diabetes. 1993 May;42(5):715-9. doi: 10.2337/diab.42.5.715.
4
Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors.
Diabetes Care. 1993 Apr;16(4):597-600. doi: 10.2337/diacare.16.4.597.
5
Angiotensin-converting enzyme inhibitors and progression of diabetic nephropathy.
Ann Intern Med. 1993 Apr 15;118(8):643-4. doi: 10.7326/0003-4819-118-8-199304150-00013.
6
Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Ann Intern Med. 1993 Apr 15;118(8):577-81. doi: 10.7326/0003-4819-118-8-199304150-00001.
7
Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.
BMJ. 1993 Jan 16;306(6871):175-82. doi: 10.1136/bmj.306.6871.175.
8
Slowing the progression of diabetic nephropathy.
N Engl J Med. 1993 Nov 11;329(20):1496-7. doi: 10.1056/NEJM199311113292012.
9
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
N Engl J Med. 1993 Nov 11;329(20):1456-62. doi: 10.1056/NEJM199311113292004.
Zotero 插件